Hospital
Health Care Authority for Baptist Health, An Affiliate of Uabhs
Health Care Authority for Baptist Health, An Affiliate of Uabhs was paid $16.69M by Medicaid between Jan 2018 and Dec 2024, across 154 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoHEALTH CARE AUTHORITY FOR BAPTIST HEALTH, AN AFFILIATE OF UABHS
MONTGOMERY, AL 36116
MONTGOMERY, AL 36116
33aNPI1700977105assigned 09/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.69M
24GClaims615,275
24DCodes billed154
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Alabama
Rank by total paid#3 of 77
Median peer was paid$1.13M
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 96,390 | $2.40M | |
| 2019 | 94,865 | $2.58M | |
| 2020 | 67,796 | $1.92M | |
| 2021 | 72,440 | $2.05M | |
| 2022 | 109,701 | $2.62M | |
| 2023 | 101,095 | $2.92M | |
| 2024incomplete | 72,988 | $2.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 41,220 | 39,318 | $2.98M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 9,850 | 9,442 | $2.88M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 49,221 | 47,150 | $2.05M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 4.9% | 7,879 | 7,539 | $823K |
| 80053 | Comprehensive metabolic panel | 4.3% | 63,066 | 53,717 | $714K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.2% | 76,227 | 65,095 | $699K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 4.0% | 19,899 | 19,117 | $675K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3.5% | 8,999 | 5,028 | $585K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.0% | 21,826 | 13,291 | $504K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.2% | 3,227 | 3,116 | $369K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.0% | 5,962 | 5,692 | $333K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.8% | 6,296 | 6,071 | $296K |
142 more codes
| 87631 | 1.5% | 4,038 | $245K | |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 19,062 | $209K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 1.2% | 8,802 | $206K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 1,999 | $196K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.0% | 232 | $168K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,546 | $167K |
| 84703 | <1% | 25,607 | $163K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,828 | $157K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,681 | $157K |
| 87070 | <1% | 10,404 | $111K | |
| 84484 | <1% | 9,968 | $106K | |
| 81003 | <1% | 34,534 | $104K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 5,384 | $103K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 601 | $101K |
| 86780 | <1% | 5,767 | $100K | |
| 84466 | <1% | 6,675 | $99K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,571 | $86K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,362 | $67K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,429 | $66K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,650 | $62K |
| 82728 | <1% | 6,878 | $60K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,168 | $58K |
| 82607 | <1% | 3,891 | $58K | |
| 83690 | <1% | 7,600 | $53K | |
| 80061 | Lipid panel | <1% | 2,912 | $53K |
| 82746 | <1% | 3,867 | $44K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,159 | $40K |
| 83540 | <1% | 6,710 | $39K | |
| 83735 | <1% | 5,417 | $39K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,353 | $38K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 66 | $29K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,168 | $29K |
| 83615 | <1% | 5,409 | $28K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,593 | $28K |
| 95816 | <1% | 624 | $27K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 960 | $26K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 239 | $26K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 120 | $24K |
| 85045 | <1% | 4,559 | $22K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,468 | $22K |
| 84702 | <1% | 1,642 | $20K | |
| 87481 | <1% | 567 | $19K | |
| 87150 | <1% | 740 | $18K | |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | <1% | 51 | $15K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 997 | $15K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 240 | $13K |
| 87081 | <1% | 1,311 | $12K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,058 | $12K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 367 | $12K |
| 86803 | <1% | 593 | $12K | |
| 74022 | <1% | 514 | $12K | |
| 96367 | <1% | 574 | $11K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 123 | $11K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 480 | $11K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 72 | $10K |
| 83605 | <1% | 836 | $10K | |
| 86300 | <1% | 921 | $10K | |
| 85027 | <1% | 1,848 | $10K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 51 | $9K |
| 83880 | <1% | 333 | $9K | |
| 86762 | <1% | 420 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,462 | $7K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 313 | $6K |
| 76801 | <1% | 201 | $6K | |
| 87340 | <1% | 409 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 600 | $5K |
| 83020 | <1% | 252 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,814 | $5K |
| 96417 | <1% | 103 | $5K | |
| 84439 | <1% | 442 | $4K | |
| 86850 | <1% | 651 | $4K | |
| 85610 | <1% | 827 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,122 | $3K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 3,491 | $3K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 53 | $3K |
| 86900 | <1% | 943 | $3K | |
| 86140 | <1% | 1,573 | $3K | |
| 86901 | <1% | 943 | $3K | |
| 82378 | <1% | 131 | $3K | |
| 97597 | <1% | 148 | $3K | |
| 80076 | <1% | 322 | $2K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 15 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,571 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 24 | $2K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 28 | $2K |
| 82105 | <1% | 78 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,089 | $2K |
| 82677 | <1% | 66 | $2K | |
| 86701 | <1% | 153 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 81 | $1K |
| 87186 | <1% | 120 | $1K | |
| 86336 | <1% | 66 | $1K | |
| 83516 | <1% | 19 | $1K | |
| 80177 | <1% | 93 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 33 | $1K |
| 86235 | <1% | 15 | $1K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 42 | $972.00 |
| 85652 | <1% | 249 | $901.50 | |
| 82248 | <1% | 128 | $842.15 | |
| 76830 | Ultrasound, transvaginal | <1% | 25 | $834.12 |
| 87040 | <1% | 69 | $818.91 | |
| 73564 | <1% | 43 | $768.03 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,178 | $656.35 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 15 | $620.40 |
| 76770 | <1% | 13 | $619.85 | |
| 86160 | <1% | 15 | $607.36 | |
| 82947 | <1% | 117 | $531.10 | |
| 82570 | <1% | 54 | $452.37 | |
| 82565 | <1% | 118 | $436.80 | |
| 87807 | <1% | 30 | $370.50 | |
| 82043 | <1% | 54 | $340.17 | |
| 86695 | <1% | 17 | $330.48 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 975 | $328.47 |
| 96415 | <1% | 18 | $300.00 | |
| 86225 | <1% | 15 | $288.60 | |
| 73630 | <1% | 13 | $260.13 | |
| 86696 | <1% | 17 | $255.00 | |
| 86038 | <1% | 13 | $244.20 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 25 | $189.40 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 25 | $189.40 |
| 96402 | <1% | 14 | $184.00 | |
| 73030 | <1% | 12 | $167.28 | |
| 85379 | <1% | 17 | $157.22 | |
| 82550 | <1% | 14 | $152.04 | |
| 74018 | <1% | 14 | $147.42 | |
| 87210 | <1% | 25 | $145.20 | |
| 86430 | <1% | 14 | $127.80 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 27 | $41.05 |
| 85730 | <1% | 16 | $32.12 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 105 | $0.00 |
| 11721 | 0% | 80 | $0.00 | |
| 81513 | 0% | 568 | $0.00 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 0% | 12 | $0.00 |
| 87563 | 0% | 58 | $0.00 | |
| 29581 | 0% | 1,245 | $0.00 | |
| 80320 | 0% | 356 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 37 | $0.00 |
| 82962 | 0% | 74 | $0.00 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | 0% | 285 | $0.00 |
| 83550 | 0% | 32 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 27 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBRUTON, CHRISTINE (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Health Care Authority for Baptist Health An Affiliate of Uabhs | Montgomery, AL | $11.99M |
| Health Care Authority for Baptist Health, An Affiliate of Uabhs | Montgomery, AL | $7.48M |
| The Health Care Authority for Baptist Health An Affiliate of Uabhs | Prattville, AL | $5.16M |
| The Health Care Authority for Baptist Health, An Affiliate of Uabhs | Montgomery, AL | $1.00M |
| The Health Care Authority for Baptist Health | Montgomery, AL | $143K |
| Montgomery Surgical Center, LTD | Montgomery, AL | $79K |
| Health Care Authority for Baptist Health, An Affiliate of Uabhs | Montgomery, AL | $8K |
| Health Care Authority for Baptist Health, An Affiliate of Uabhs | Prattville, AL | $261.54 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.